{Reference Type}: Case Reports
{Title}: Safety of rezafungin as a long-term treatment option in two patients with complicated fungal infections: two cases from Lecco Hospital (Italy).
{Author}: Ponta G;Morena V;Strano M;Molteni C;Pontiggia S;Cavalli EM;Grancini A;Mauri C;Castagna A;Galanti A;Piconi S;
{Journal}: Antimicrob Agents Chemother
{Volume}: 68
{Issue}: 8
{Year}: 2024 Aug 7
{Factor}: 5.938
{DOI}: 10.1128/aac.00750-24
{Abstract}: Rezafungin is an echinocandin characterized by a long elimination half-life which allows for weekly administration. It has been recently approved for the treatment of candidemia. Few data are available about the long-term use of rezafungin and its use for deep infections like endocarditis and osteomyelitis. We describe our experience with its prolonged use in two azole-resistant Candida infections: a case of sacral osteomyelitis and a prosthetic valve endocarditis also involving a thoracic endovascular aneurysm repair.